Submitted by Anonymous (not verified) on 27 November 2023 - 15:11
Human medicines European public assessment report (EPAR): Orserdu, elacestrant, Breast Neoplasms, Date of authorisation: 15/09/2023, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Orserdu, elacestrant, Breast Neoplasms, Date of authorisation: 15/09/2023, Status: Authorised